J&J science lead Paul Stoffels set to retire amid brain trust shakeup at world's largest drugmaker
Paul Stoffels, the scientific lead behind J&J’s refresh of its hallowed Janssen unit and the creation of the company’s single-shot Covid-19 vaccine, will retire at the end of the year, joining CEO Alex Gorsky on the way out the door and setting up a new era of leadership at the industry’s biggest drugmaker.
As the man most responsible for J&J’s hard pivot back into R&D over the course of the past decade, Stoffels was responsible for propping up an oncology R&D unit that ranks among the largest in the industry as well as driving J&J’s efforts across a broad range of therapeutic areas.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.